Our preclinical findings support those of Herremans et al35, who reported that in PDAC data from The Cancer Genome Atlas and Gene Expression Omnibus databases, IL-1 was associated with significant changes in the PDAC tumor immune landscape and the expression of tumor immune checkpoint proteins. Here, IL1B is linked to neoplasm.